BRIEF-ProMetic announces the addition of tympanic membrane perforations to its plasminogen's targeted indications

Tue Sep 6, 2016 6:00am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Sept 6 (Reuters) - ProMetic Life Sciences Inc

* Will be pursuing tympanic membrane perforations as one of its new plasma-derived plasminogen targeted clinical indications

* Expects to file its clinical trial application in Q4 2016

* Expects to initiate clinical trial in Sweden in patients suffering from chronic tympanic membrane perforations in H1 2017 Source text for Eikon: Further company coverage: